卡瑞利珠单抗联合阿帕替尼治疗复发/转移性鼻咽癌的有效性和安全性：一项单臂荟萃分析。
Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.
作者信息
Li Yanmei, Liang Yongfu, Ye Peichang, Chen Guoan, Zhang Yimin, Chen Meixia, Xiong Wenhua, Yang Xiuhao, Zhang Xiaowen
机构信息
Department of Otorhinolaryngology, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
Ophthalmology Department, The Fifth People's Hospital of Nanhai District, Foshan, 528231, Guangdong, China.
出版信息
Eur Arch Otorhinolaryngol. 2025 May 31. doi: 10.1007/s00405-025-09482-x.
PURPOSE
To evaluate the efficacy and safety of camrelizumab combined with apatinib in the treatment of recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) and provide a basis for clinical application.
METHODS
PubMed, Cochrane Library, Embase, and Web of Science databases were searched until July 19, 2024 for relevant studies. Data extraction and risk of bias assessment were conducted. Meta-analysis was performed using R software.
RESULTS
Four single-arm trials with a total of 205 patients were included, with an overall survival rate of 78%, a progression-free survival rate of 45%, an objective response rate of 60%, and a disease control rate of 76%. Common adverse reactions were anemia (45%), leukopenia (46%), and fatigue (53%). The incidence of grade 3 or above adverse reactions was less than 10%, except for hypertension (16%).
CONCLUSION
Camrelizumab combined with apatinib showed favorable efficacy and safety in the treatment of RM-NPC, providing an important reference for clinical treatment strategies.
目的
评估卡瑞利珠单抗联合阿帕替尼治疗复发/转移性鼻咽癌（RM-NPC）的疗效和安全性，为临床应用提供依据。
方法
检索PubMed、Cochrane图书馆、Embase和Web of Science数据库至2024年7月19日的相关研究。进行数据提取和偏倚风险评估。使用R软件进行荟萃分析。
结果
纳入4项单臂试验，共205例患者，总生存率为78%，无进展生存率为45%，客观缓解率为60%，疾病控制率为76%。常见不良反应为贫血（45%）、白细胞减少（46%）和疲劳（53%）。3级及以上不良反应发生率低于10%，高血压除外（16%）。
结论
卡瑞利珠单抗联合阿帕替尼治疗RM-NPC显示出良好的疗效和安全性，为临床治疗策略提供了重要参考。
Zotero 插件